Revisiting the role of ergots in the treatment of migraine and headache

Headache

Volumn 50, Issue 8, 2010, Pages 1353-1361

  Baron, Eric P ^a   Tepper, Stewart J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

DHE; ergotamine; ergots; headache; migraine; triptans

Indexed keywords

ALMOTRIPTAN; CAFERGOT; CAFFEINE; CARBASALATE CALCIUM; DIHYDROERGOTAMINE; ELETRIPTAN; ERGOT DERIVATIVE; ERGOTAMINE TARTRATE; FROVATRIPTAN; METOCLOPRAMIDE; NAPROXEN PLUS SUMATRIPTAN; NARATRIPTAN; RIZATRIPTAN; SEROTONIN RECEPTOR; SUMATRIPTAN; TRIPTAN DERIVATIVE; ZOLMITRIPTAN;

BRAIN BLOOD VESSEL; BRAIN CORTEX; BRAIN STEM RESPONSE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DOSAGE FORM COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DYSPHORIA; HEADACHE; HUMAN; MIGRAINE; NAUSEA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RECEPTOR BINDING; RECURRENT DISEASE; REVIEW; SIDE EFFECT; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; VASOCONSTRICTION; VOMITING;

ERGOT ALKALOIDS; HEADACHE DISORDERS; HISTORY, 15TH CENTURY; HISTORY, 16TH CENTURY; HISTORY, 17TH CENTURY; HISTORY, 18TH CENTURY; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, ANCIENT; HISTORY, MEDIEVAL; HUMANS; MIGRAINE DISORDERS; TRYPTAMINES;

EID: 77956328598     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2010.01662.x     Document Type: Review

References (42)

1. Zavaleta EG, Fernandez BB, Grove MK, Kaye MD. St. anthony's fire (ergotamine induced leg ischemia) - A case report and review of the literature. Angiology. 2001 52 : 349 356.
2. De Costa C. St anthony's fire and living ligatures: A short history of ergometrine. Lancet. 2002 359 : 1768 1770.
3. Schuman SH. Plant chemicals: Poisons and cures. J Agromedicine. 2003 9 : 17 21.
4. Eadie MJ. Ergot of rye-the first specific for migraine. J Clin Neurosci. 2004 11 : 4 7.
5. Koehler PJ, Isler H. The early use of ergotamine in migraine. edward woakes' report of 1868, its theoretical and practical background and its international reception. Cephalalgia. 2002 22 : 686 691.
6. Tfelt-Hansen PC, Koehler PJ. History of the use of ergotamine and dihydroergotamine in migraine from 1906 and onward. Cephalalgia. 2008 28 : 877 886.
7. Bigal ME, Tepper SJ. Ergotamine and dihydroergotamine: A review. Curr Pain Headache Rep. 2003 7 : 55 62.
8. Silberstein SD, McCrory DC. Ergotamine and dihydroergotamine: History, pharmacology, and efficacy. Headache. 2003 43 : 144 166.
9. Tepper SJ, Millson D. Safety profile of the triptans. Expert Opin Drug Saf. 2003 2 : 123 132.
10. Tepper SJ. Safety and rational use of the triptans. Med Clin North Am. 2001 85 : 959 970.
11. MaassenVanDenBrink A, Reekers M, Bax WA, Ferrari MD, Saxena PR. Coronary side-effect potential of current and prospective antimigraine drugs. Circulation. 1998 98 : 25 30.
12. MacIntyre PD, Bhargava B, Hogg KJ, Gemmill JD, Hillis WS. Effect of subcutaneous sumatriptan, a selective 5HT1 agonist, on the systemic, pulmonary, and coronary circulation. Circulation. 1993 87 : 401 405.
13. Markowitz S, Saito K, Moskowitz MA. Neurogenically mediated plasma extravasation in dura mater: Effect of ergot alkaloids. A possible mechanism of action in vascular headache. Cephalalgia. 1988 8 : 83 91.
14. Tzanck MA. Le traitement des migraines par le tartrate d'ergotamine. Bull Soc Med. 1928 44 : 1057.
15. Lennox WG. Ergonovine versus ergotamine as a terminator or migraine headaches. Am J Med Sci. 1938 195 : 458 468.
16. Ibraheem JJ, Paalzow L, Tfelt-Hansen P. Low bioavailability of ergotamine tartrate after oral and rectal administration in migraine sufferers. Br J Clin Pharmacol. 1983 16 : 695 699.
17. Sanders SW, Haering N, Mosberg H, Jaeger H. Pharmacokinetics of ergotamine in healthy volunteers following oral and rectal dosing. Eur J Clin Pharmacol. 1986 30 : 331 334.
18. Tfelt-Hansen P, Saxena PR, Dahlof C, et al. Ergotamine in the acute treatment of migraine: A review and european consensus. Brain. 2000 123 : 9 18.
19. Olesen J. The Headaches, 3rd edn. Philadelphia, PA : Lippincott Williams & Wilkins 2006.
20. Dahlof C. Clinical efficacy and tolerability of sumatriptan tablet and suppository in the acute treatment of migraine: A review of data from clinical trials. Cephalalgia. 2001 21 (Suppl. 1 9 12.
21. Meyler WJ. Side effects of ergotamine. Cephalalgia. 1996 16 : 5 10.
22. Roth BL. Drugs and valvular heart disease. N Engl J Med. 2007 356 : 6 9.
23. Andersen AR, Tfelt-Hansen P, Lassen NA. The effect of ergotamine and dihydroergotamine on cerebral blood flow in man. Stroke. 1987 18 : 120 123.
24. de Hoon JN, Poppe KA, Thijssen HH, Struijker-Boudier HA, Van Bortel LM. Dihydroergotamine: Discrepancy between arterial, arteriolar and pharmacokinetic data. Br J Clin Pharmacol. 2001 52 : 45 51.
25. Aellig WH, Rosenthaler J. Venoconstrictor effects of dihydroergotamine after intranasal and intramuscular administration. Eur J Clin Pharmacol. 1986 30 : 581 584.
26. Winner P, Dalessio D, Mathew N, et al. Concomitant administration of antiemetics is not necessary with intramuscular dihydroergotamine. Am J Emerg Med. 1994 12 : 138 141.
27. Winner P, Dalessio D, Mathew N, et al. Office-based treatment of acute migraine with dihydroergotamine mesylate. Headache. 1993 33 : 471 475.
28. Hoskin KL, Kaube H, Goadsby PJ. Central activation of the trigeminovascular pathway in the cat is inhibited by dihydroergotamine. A c-fos and electrophysiological study. Brain. 1996 119 : 249 256.
29. Saper JR, Silberstein S. Pharmacology of dihydroergotamine and evidence for efficacy and safety in migraine. Headache. 2006 46 (Suppl. 4 S171 S181.
30. Callaham M, Raskin N. A controlled study of dihydroergotamine in the treatment of acute migraine headache. Headache. 1986 26 : 168 171.
31. Raskin NH. Modern pharmacotherapy of migraine. Neurol Clin. 1990 8 : 857 865.
32. Silberstein SD, Young WB. Safety and efficacy of ergotamine tartrate and dihydroergotamine in the treatment of migraine and status migrainosus. Working panel of the headache and facial pain section of the American Academy of Neurology. Neurology. 1995 45 : 577 584.
33. Winner P, Ricalde O, Le Force B, Saper J, Margul B. A double-blind study of subcutaneous dihydroergotamine vs subcutaneous sumatriptan in the treatment of acute migraine. Arch Neurol. 1996 53 : 180 184.
34. Saper JR, Silberstein S. Pharmacology of dihydroergotamine and evidence for efficacy and safety in migraine. Headache. 2006 46 (Suppl. 4 S171 S181.
35. Scott AK. Dihydroergotamine: A review of its use in the treatment of migraine and other headaches. Clin Neuropharmacol. 1992 15 : 289 296.
36. Shrewsbury SB, Cook RO, Taylor G, Edwards C, Ramadan NM. Safety and pharmacokinetics of dihydroergotamine mesylate administered via a novel (tempo) inhaler. Headache. 2008 48 : 355 367.
37. Shrewsbury SB, Kori SH, Miller SD, Pedinoff A, Weinstein S. Randomized, double-blind, placebo-controlled study of the safety, tolerability and pharmacokinetics of MAP0004 (orally-inhaled DHE) in adult asthmatics. Curr Med Res Opin. 2008 24 : 1977 1985.
38. Aurora SK, Rozen TD, Kori SH, Shrewsbury SB. A randomized, double blind, placebo-controlled study of MAP0004 in adult patients with migraine. Headache. 2009 49 : 826 837.
39. Silberstein SD, Kori SH, Tepper SJ, et al. Efficacy and tolerability of MAP0004, a novel inhaled therapy, in treating acute migraine. Cephalalgia. 2009 29 (Suppl. 1 12 13.
40. Rapoport AM, Tepper SJ, Bigal ME, Sheftell FD. The triptan formulations: How to match patients and products. CNS Drugs. 2003 17 : 431 447.
41. Goldstein DJ, Roon KI, Offen WW, et al. Selective seratonin 1F (5-HT(1F)) receptor agonist LY334370 for acute migraine: A randomised controlled trial. Lancet. 2001 358 : 1230 1234.
42. Silberstein SD, Lipton RB, Dodick D, Wolff HG. Wolff's Headache and Other Head Pain, 8th edn. New York : Oxford University Press 2008.